PDF Archive

Easily share your PDF documents with your contacts, on the Web and Social Networks.

Share a file Manage my documents Convert Recover PDF Search Help Contact



Osteosarcoma Clinical Trials .pdf



Original filename: Osteosarcoma Clinical Trials.pdf
Title: PowerPoint Presentation
Author: evan

This PDF 1.5 document has been generated by Microsoft® PowerPoint® 2010, and has been sent on pdf-archive.com on 06/05/2014 at 16:43, from IP address 109.185.x.x. The current document download page has been viewed 692 times.
File size: 509 KB (5 pages).
Privacy: public file




Download original PDF file









Document preview


Eleison’s mission is to acquire, develop, and
commercialize clinical stage drug candidates for
“orphan” cancers, providing new hope for patients
with rare, life-threatening diseases.
ABOUT ELEISON’S CLINICAL TRIALS
Clinical trials are an important and necessary component of the drug
development process, in order to evaluate the safety and efficacy of new drug
candidates. Eleison is currently conducting clinical trials of its two drug
candidates at leading hospitals and cancer treatment centers in the United
States and around the world. Read More…

Eleison is currently developing ILC, a breakthrough
therapeutic for the treatment of patients with a
rare form of bone cancer known as osteosarcoma .
INHALED LIPID-COMPLEXED CISPLATIN - “ILC”
● Engineered specifically for nebulized lung delivery.
● Patented lipid formulation of cisplatin in ~0.4 μm particles deliver sustained
drug release in the lung.
● Concentrations in lung at least 10x higher and systemic toxicities much lower
than intravenous dosing of cisplatin.
● Safety data showed no hematologic toxicity, nephrotoxicity, ototoxicity, or
neurotoxicity.

ILC has been tested in dozens of patients in several clinical trials.
ILC clinical trial activity:
● ILC has been tested in patients with NSCLC (non-small cell lung cancer),
bronchoalveolar cancer, and osteosarcoma.
● ILC is currently being evaluated in a phase II clinical trial, to test the safety and
efficacy of ILC in patients with osteosarcoma which has spread to the lungs.
● Participating hospitals in the ongoing clinical trial for osteosarcoma include
Memorial Sloan-Kettering, Montefiore Children’s Hospital, Moffitt Cancer
Center, University of Chicago Children’s Hospital, Children’s Hospital of Los
Angeles, University of Utah Primary Children’s Hospital, Washington University
(St. Louis), and others soon to be added. See www.clinicaltrials.gov for more
information about Eleison’s clinical trial of ILC.

Osteosarcoma is a rare and often fatal bone cancer.
About Osteosarcoma:
● Osteosarcoma is primarily a disease of teenagers and young adults.

● 500 new cases annually in US, 800 new cases annually in Europe.
● Upon diagnosis, patients are treated with surgery and systemic combination
chemotherapy.
● 30% to 35% of patients fail first-line therapy, most commonly with
metastatic recurrence only in the lungs, with poor prognosis (five year
survival of such patients is < 25%)
● No drugs are currently approved in the U.S. to treat osteosarcoma patients
who have failed first-line therapy.

For More Information:
Eleison Pharmaceuticals, LLC
263 13th Avenue South, Suite 375
St. Petersburg, FL 33701
ph: 215-554-3530
info@eleison-pharma.com


Related documents


osteosarcoma clinical trials
9783662490105 c1
v15n4s57revisiting
ambaird bio
bone cancer treatment
chemo


Related keywords